NRIX

Nurix Therapeutics Stock Analysis

AI Rating

Low
  • Quality0/10
  • Growth↓ 2/10
  • Value↓ 0/10
Nurix Therapeutics sales and earnings growth
NRIX Growth
Fair
  • Revenue Y/Y↑ 27.23%
  • EPS Y/Y↓ -13.21%
  • FCF Y/Y↓ -34.85%
Nurix Therapeutics gross and profit margin trends
NRIX Profitability
Fair
  • Gross margin ↑ 100.00%
  • EPS margin↓ -411.40%
  • ROIC 5Y↓ -57.72%
Nurix Therapeutics net debt vs free cash flow
NRIX Risk
Great
  • Debt / Equity↓ 0.1
  • Debt / FCF↓ 0.0
  • Interest coverage↓ NA

Nurix Therapeutics stock volatility is in-line with the overall market. We give it a Great risk rating.

↗ More Biotechnology stocks